Unichem Laboratories Ltd (UNICHEMLAB) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Unichem Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Unaudited financial Results for Q2FY2027
Financial Result · 04 Nov 2026, 7:31 pm
Unichem Laboratories Reports Q2 FY27 Results: Consolidated PAT Reaches ₹22.22 Crore Unichem Laboratories reported consolidated revenue from operations of ₹640.22 crore for Q2 ended 30th Sep'26, up 10.58% YoY from ₹578.96 crore and up 1.20% QoQ. Consolidated profit before exceptional items stood at ₹51.63 crore versus ₹47.44 crore in Q2 FY26. Following an exceptional claim provision of ₹24.26 crore related to UK Perindopril litigation by subsidiary Niche Generics, net profit after tax reached ₹22.22 crore, rebounding from a loss of ₹11.89 crore YoY. Standalone revenue grew 12.61% YoY to ₹401.90 crore with PAT of ₹1.49 crore.
Unaudited Financial Statements (Consolidated & Standalone) for the second quarter and half year ended 30th September 2026.
Outcome · 04 Nov 2026, 7:25 pm
Unichem Laboratories Reports Q2 Results with Consolidated Revenue at ₹640.22 Crore Unichem Laboratories reported consolidated revenue from operations of ₹640.22 crore for the quarter ended 30th Sep'26, up 10.58% YoY from ₹578.96 crore and 1.20% QoQ from ₹632.62 crore. Consolidated profit after tax reached ₹22.22 crore, reversing a net loss of ₹11.89 crore in the year-ago period, despite an exceptional expense of ₹24.26 crore related to UK litigation claim provisions. On a standalone basis, revenue rose to ₹401.90 crore from ₹356.90 crore YoY, with net profit standing at ₹1.49 crore.
Unichem Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 04 Nov 2026, 7:24 pm
Unichem Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 640 (+10.6% YoY | +1.2% QoQ) ■ EBITDA: 74.5 (+12.5% YoY | +6.5% QoQ) ■ EBITDA Margin (%): 11.6 (+20 bps YoY | +57 bps QoQ) ■ PAT: 22.2 (Loss to Profit YoY | -46.4% QoQ) ■ EPS (INR): 3.14 (Loss to Profit YoY | -46.7% QoQ)
To consider and approve the unaudited financial results for the period ended September 30, 2026
Intimation · 04 Nov 2026, 5:30 am
UNICHEM LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 04 Nov 2026, 5:30 am
Unichem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Board Meeting Intimation ....
Intimation · 04 Nov 2026, 5:30 am
Unichem Laboratories Schedules Board Meeting for Q2 FY27 Financial Results Unichem Laboratories Ltd. announced that its Board of Directors is scheduled to meet on 4th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the second quarter and half-year ended 30th Sep'26.
Announcement under regulation 30 (LODR) - USFDA Inspection at Goa formulation Facility
Others (Uncategorized) · 26 Sept 2026, 10:34 pm
Unichem Laboratories Receives Five USFDA Observations for Goa Formulation Facility The USFDA concluded an inspection at Unichem Laboratories Limited's Goa formulation facility in Pilerne, Bardez, conducted from 21st Sep'26 to 26th Sep'26. The inspection concluded with five observations relating to procedural enhancements. The company stated it will submit the necessary response to the USFDA within the stipulated 15-day timeline.
Disclosure u/r. 30 of SEBI (LODR) Regulations, 2015
Others (Uncategorized) · 19 Sept 2026, 5:04 pm
Unichem Laboratories Receives Adverse Tax Order-In-Appeal Disallowing Penalty Relief Unichem Laboratories received an Order-In-Appeal on 18th Sep'26 from the Commissioner (Appeals Thane) regarding the cross charge of common services. The order disallowed the company's appeal against a penalty of Rs 87.07 cr under Section 74(1) and Section 122(2)(b) of the CGST Act, 2017 (and Maharashtra SGST Act), alongside an interest liability of Rs 6.59 cr for delayed tax payments. The company confirmed no material operational impact and plans to pursue further appeals based on legal advice within prescribed timelines.
Extension of the Exercise period for the options granted and vested under Unichem Employee Stock Option Scheme 2018.
Others (Uncategorized) · 11 Sept 2026, 9:00 pm
Unichem Laboratories Extends ESOP Exercise Period to Mar'27 Unichem Laboratories' Nomination and Remuneration Committee approved extending the exercise period for vested stock options under its ESOP Scheme 2018 via circular resolution on 11th Sep'26. The deadline for 250,000 options under Tranche 1 (vested 1st Jul'24) and 125,000 options under Tranche 2 (vested 1st May'25) has been extended from 30th Sep'26 to 31st Mar'27. All other terms and conditions governing the granted options remain unchanged.
Significant increase in the volume of securities.
Others (Uncategorized) · 26 Aug 2026, 9:10 pm
Unichem Labs Attributes Share Volume Spike to Market Forces In response to a BSE clarification sought on 26th Aug'26 regarding a significant increase in security volume, Unichem Laboratories stated the movement is "purely market driven." The company affirmed it has no specific comment to offer on the matter. Unichem further clarified that it has consistently made all timely disclosures required under SEBI (LODR) Regulations, 2015 and will continue to do so, indicating no undisclosed price-sensitive information is pending from its end.
The Exchange has sought clarification from Unichem Laboratories Ltd on August 26, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
Others (Uncategorized) · 26 Aug 2026, 7:33 pm
Disclosure of Voting Results alongwith Scrutinizer''s Report dated 12th August 2026.
Annual General Meeting · 12 Aug 2026, 5:39 pm
Unichem Labs: Shareholders Approve All Resolutions at 63rd AGM At its 63rd AGM on 11th Aug'26, Unichem Laboratories secured shareholder approval for all five resolutions. Key approvals include the adoption of FY26 financial statements and the re-appointment of Pabitrakumar Bhattacharyya as MD & CEO for three years, a special resolution. Other ordinary resolutions passed were the re-appointment of Mr. Bhattacharyya as a director and ratification of cost auditor remuneration. All proposals passed with nearly unanimous support, with total votes against all resolutions combined being minimal. The promoter group voted entirely in favour.
Proceedings of the 63rd Annual General Meeting.
Annual General Meeting · 11 Aug 2026, 10:17 pm
Pl. find enclosed financial statement of FY 2026-2027 (CFS & SFS)
Financial Result · 11 Aug 2026, 7:24 pm
Unichem Labs Q1 FY27 Results: Revenue Grows 20.1% YoY, PAT Rebounds Unichem Laboratories reported consolidated results for Q1 ending 30 Jun'26, showing a strong turnaround. Revenue from operations grew 20.1% YoY and 10.0% QoQ to ₹632.62 crores. The company posted a profit after tax of ₹41.47 crores, a significant recovery from a ₹10.47 crore loss in the prior-year quarter and up from ₹10.91 crores QoQ. This performance was driven by top-line growth and lower material costs, which decreased to 30.0% of revenue from 41.3% YoY. Basic EPS stood at ₹5.89, versus (₹1.49) YoY.
Unaudited Financial Statements (Consolidated & Standalone) for the first quarter ended 30th June 2026 alongwith Limited Review report by Auditors
Outcome · 11 Aug 2026, 7:19 pm
Unichem Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Crore) ■ Revenue: 633 (+20.1% YoY | +10.0% QoQ) ■ EBITDA: 69.9 (+211.0% YoY | +46.7% QoQ) ■ EBITDA Margin (%): 11.1 (+678 bps YoY | +277 bps QoQ) ■ PAT: 41.5 (Loss to Profit YoY | +280.1% QoQ) ■ EPS (INR): 5.89 (Loss to Profit YoY | +280.0% QoQ)
Disclosure u/r. 30 of SEBI (LODR), 2015
Others (Uncategorized) · 29 Jul 2026, 6:30 pm
Unichem Labs' Tax Appeal Partially Allowed; Faces Rs. 10.59 Lakh Demand Unichem Laboratories announced its appeal regarding GSTR TRAN 1 credit was partially allowed by the Additional Commissioner, CGST (Appeals), Dehradun. The initial disallowance was for Rs. 73.03 lakh. Following the order received on 28th Jul'26, the company now faces a demand of Rs. 10.59 lakh plus interest. Unichem states there is no material financial impact and, based on legal advice, intends to file a further appeal against the order within the prescribed timelines to contest the remaining demand.
Unichem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve The Unaudited Financial ....
Intimation · 11 Aug 2026, 5:30 am
Unichem Labs Board Meeting Set for Q1 FY27 Results Unichem Laboratories (NSE: UNICHEMLAB, BSE: 506690) has scheduled a Board of Directors meeting on 11th Aug'26. The agenda includes the consideration and approval of the company's unaudited standalone and consolidated financial results for the first quarter ending 30th Jun'26. This key meeting will set the financial tone for the start of the fiscal year.
Pl. find attached response to clarification sought on price movement
Others (Uncategorized) · 11 Jul 2026, 2:56 am
Unichem Labs Clarifies Significant Share Price Movement In a filing dated 10 Jul'26, Unichem Laboratories (BSE: 506690) responded to a BSE query regarding significant share price movement. The company stated the price increase appears to be purely market-driven. Management confirmed it is not aware of any undisclosed material information or events that could have caused the surge. Unichem asserted it has complied with all SEBI disclosure requirements and has no further comments to offer on the matter at this time.
The Exchange has sought clarification from Unichem Laboratories Ltd on July 10, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 10 Jul 2026, 11:37 pm
Intimating to shareholders - Non-email cases
Others (Uncategorized) · 06 Jul 2026, 5:30 pm
Unichem Labs Schedules 63rd AGM for 11th August 2026 Unichem Laboratories has scheduled its 63rd Annual General Meeting (AGM) for 11th Aug'26 at 3:30 p.m. IST via video conferencing. The company has dispatched its FY26 Annual Report to shareholders who have not registered an email address as of the 26th Jun'26 cut-off date. Unichem also reminded physical security holders to update KYC details, including PAN and bank information, to ensure eligibility for receiving payments like dividends electronically, a mandatory requirement effective from 1st Apr'24 per SEBI circulars.
Issued letters to those shareholders whose email address are not registered with the Company/Depository Particeipant/ Registrar and Share Transfer Agent, Providing the web-link from where ....
Others (Uncategorized) · 06 Jul 2026, 5:14 pm
Notice of 63rd AGM - 11th August 2026
Annual General Meeting · 03 Jul 2026, 2:31 pm
Business Responsibility and Sustainability Report for FY 2026
Others (Uncategorized) · 03 Jul 2026, 2:28 pm
Unichem Laboratories' FY26 Sustainability Report: Key Operating & Financial Metrics Unichem Laboratories reported a turnover of ₹1,412.29 crores and a net worth of ₹2,627.10 crores for FY26. Exports contributed 97.6% to total turnover. The company serves 14 states in India and 65 countries internationally. The permanent employee turnover rate decreased to 31.05% from 33.05% YoY. In FY26, the company paid a €16.75 million penalty related to a 2005 patent dispute. CSR spending was not mandatory due to average net losses in the preceding three years. Total energy consumption rose to 6.44 million GJ from 5.81 million GJ.
Annual Report FY 2026
Others (Uncategorized) · 03 Jul 2026, 2:23 pm
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Equity Intelligence India Pvt Ltd
Acquisition/ Disposal of Shares · 12 Jun 2026, 10:54 pm
Equity Intelligence India Acquires Additional Stake in Unichem Laboratories Equity Intelligence India, on behalf of its clients, acquired 300,000 shares of Unichem Laboratories via an open market transaction on 11-Jun'26. This purchase represents 0.43% of the company's total share capital. Following the acquisition, the acquirer's total holding in Unichem Labs decreased from 694,375 shares (0.99% stake) to 394,375 shares (0.56% stake). The transaction details indicate a sale, despite being filed under an acquisition disclosure. The acquirer is not part of the promoter group.